Supplementary Material for: Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma
H. Marescassier(Centre Hospitalier Universitaire de Poitiers), Marie Masson-Regnault, M. Beylot‐Barry(Université de Bordeaux), Franck Marie Leclère(Centre Hospitalier Universitaire de Poitiers), L. Dousset(Centre Hospitalier Universitaire de Bordeaux), E. Wierzbicka-Hainaut(Université de Poitiers), C. Bédane(Central Michigan University), L. Vaillant(Centre Hospitalier Universitaire de Tours), P. Celérier(Centre Hospitalier de La Rochelle)
Cited by 0
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
|Journal of Clinical Oncology|2015|419
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study
|Annals of the Rheumatic Diseases|2017|302
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.
|PubMed|2000|267
Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response
|Science Translational Medicine|2013|246